What is known and objective: Treatment for diffuse large B-cell lymphoma (DLBCL) in persons with AIDS consists of chemotherapy alongside antiretroviral therapy (ART). To determine optimal HIV treatment, drug-drug interactions, toxic effects and ART resistance must be considered.
Case description: A 40-year-old man with drug-resistant HIV and DLBCL initiating chemotherapy which had drug interactions with his ART. During chemotherapy, darunavir/cobicistat was held and ibalizumab-uiyk was started to ensure he was on three active HIV medications.
What is new and conclusion: Ibalizumab-uiyk has no known drug-drug interactions and may be used as bridge therapy for patients with drug-resistant HIV undergoing chemotherapy.
Keywords: AIDS; HIV and lymphoma; diffuse large B-cell lymphoma; drug-drug interaction chemotherapy and antiretroviral therapy; drug-resistant HIV-1 infection; ibalizumab-uiyk.
© 2021 John Wiley & Sons Ltd.